SCHEMBL23964237

SCHEMBL23964237

Brc1ccc2[nH]c(CN3CCN(c4ccncc4)CC3)cc2c1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 12/20 0.54
DRD3 P35462 12/20 0.54
DRD4 P21917 8/20 0.54
HTR1A P08908 1/20 0.49
ADRA2A P08913 1/20 0.49
ADRA2B P18089 1/20 0.49
ADRA2C P18825 1/20 0.49
OPRK1 P41145 1/20 0.49
IDO1 P14902 5/20 0.46
ACHE P22303 1/20 0.43
HRH4 Q9H3N8 1/20 0.43
TSHR P16473 1/20 0.41
TDO2 P48775 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30042123 0.90 DRD2 (0.54) DRD2DRD3DRD4HTR1AADRA2A
SCHEMBL23964180 0.90 DRD2 (0.54) DRD2DRD3DRD4HTR1AADRA2A
SCHEMBL23964260 0.85 DRD4 (0.54) DRD2DRD3DRD4HTR1AADRA2A
SCHEMBL30041683 0.85 DRD4 (0.54) DRD2DRD3DRD4HTR1AADRA2A
SCHEMBL23964265 0.85 DRD4 (0.54) DRD2DRD3DRD4HTR1AADRA2A
SCHEMBL23964261 0.85 DRD4 (0.64) DRD2DRD3DRD4HTR1AADRA2A
SCHEMBL30041451 0.84 HRH4 (0.63) DRD2DRD3DRD4HTR1AADRA2A
SCHEMBL23964200 0.84 HRH4 (0.63) DRD2DRD3DRD4HTR1AADRA2A
SCHEMBL23964181 0.82 HRH3 (0.53) DRD2DRD3DRD4HTR1AADRA2A
SCHEMBL23964157 0.82 SLC2A1 (0.54) DRD2DRD3DRD4HTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119775261-A Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2025-04-08 CN disclosed
CN-115427404-B Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2024-12-13 CN disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
EP-4139291-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF Anima Biotech Inc. (US) 2023-03-01 EP disclosed
CN-115427404-A Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2022-12-02 CN disclosed
WO-2021216665-A9 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-12-02 WO disclosed
WO-2021216665-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 DRD2 4780/4885DRD3 4747/4885DRD4 4746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.